Apremilast Pregnancy Exposure Registry

• Status: Recruiting
• Trial end date: 2024-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of the Apremilast Pregnancy Exposure Registry is to monitor planned and unplanned pregnancies exposed to apremilast and to evaluate the safety of this medication relative to specified pregnancy outcomes, and to evaluate potential effects of prenatal apremilast exposure on infant health status through one year of age.

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of California, San Diego
• Collaborators: Celgene; The Organization of Teratology Information Specialists
• Treatments: Apremilast; Thalidomide

Criteria

Inclusion Criteria:

• Pregnant

Exclusion Criteria:

-